{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:04:59Z","timestamp":1791669899306,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Santhera"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00415-026-13711-6","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T13:33:43Z","timestamp":1772544823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to\u2009<\u200918-year-old boys with duchenne muscular dystrophy"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-8001","authenticated-orcid":false,"given":"Hanns","family":"Lochm\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-8324","authenticated-orcid":false,"given":"Hernan","family":"Gonorazky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-2507","authenticated-orcid":false,"given":"Elisa","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5795-9955","authenticated-orcid":false,"given":"Jean K.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8820-693X","authenticated-orcid":false,"given":"Alberto","family":"Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-0788","authenticated-orcid":false,"given":"Amanda","family":"Yaworski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-0108","authenticated-orcid":false,"given":"Maryam","family":"Oskoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3682-8293","authenticated-orcid":false,"given":"Anne Marie","family":"Sbrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-1704","authenticated-orcid":false,"given":"Kathryn","family":"Selby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4183-0155","authenticated-orcid":false,"given":"Ana","family":"de Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4650-7232","authenticated-orcid":false,"given":"Laura","family":"McAdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0906-6198","authenticated-orcid":false,"given":"Ekaterina","family":"Gresko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1081-1071","authenticated-orcid":false,"given":"Aki","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0851-3423","authenticated-orcid":false,"given":"Catherine","family":"Dutreix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6470-5139","authenticated-orcid":false,"given":"Eric P.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"13711_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"M Koenig","year":"1987","unstructured":"Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509\u2013517. https:\/\/doi.org\/10.1016\/0092-8674(87)90504-6","journal-title":"Cell"},{"key":"13711_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr., Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4","journal-title":"Cell"},{"key":"13711_CR3","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/14740338.2024.2394578","volume":"23","author":"E Czifrus","year":"2024","unstructured":"Czifrus E, Berlau DJ (2024) Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review. Expert Opin Drug Saf 23:1237\u20131247. https:\/\/doi.org\/10.1080\/14740338.2024.2394578","journal-title":"Expert Opin Drug Saf"},{"key":"13711_CR4","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/wnl.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT 3rd, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM (2016) Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology 87:2123\u20132131. https:\/\/doi.org\/10.1212\/wnl.0000000000003217","journal-title":"Neurology"},{"key":"13711_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","volume":"86","author":"D Gloss","year":"2016","unstructured":"Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M (2016) Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:465\u2013472. https:\/\/doi.org\/10.1212\/WNL.0000000000002337","journal-title":"Neurology"},{"key":"13711_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112","volume":"102","author":"UJ Dang","year":"2024","unstructured":"Dang UJ, Damsker JM, Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, Mah JK, Deconinck N, Goemans NM, Haberlova J, Straub V, Mengle-Gaw L, Schwartz BD, Harper A, Shieh PB, De Waele L, Castro D, Yang ML, Ryan MM, McDonald CM, Tulinius M, Webster RI, McMillan HJ, Kuntz N, Rao VK, Baranello G, Spinty S, Childs AM, Sbrocchi AM, Selby KA, Monduy M, Nevo Y, Vilchez JJ, Nascimento-Osorio A, Niks EH, De Groot IJM, Katsalouli M, Van Den Anker JN, Ward LM, Leinonen M, D\u2019Alessandro AL, Hoffman EP (2024) Efficacy and safety of Vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial. Neurology 102:e208112. https:\/\/doi.org\/10.1212\/WNL.0000000000208112","journal-title":"Neurology"},{"key":"13711_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/currents.md.d18deef7dac96ed135e0dc8739917b6e","author":"K Kinnett","year":"2017","unstructured":"Kinnett K, Noritz G (2017) The PJ nicholoff steroid protocol for Duchenne and Becker muscular dystrophy and adrenal suppression. PLoS Curr. https:\/\/doi.org\/10.1371\/currents.md.d18deef7dac96ed135e0dc8739917b6e","journal-title":"PLoS Curr"},{"key":"13711_CR8","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","volume":"109","author":"F Beuschlein","year":"2024","unstructured":"Beuschlein F, Else T, Bancos I, Hahner S, Hamidi O, van Hulsteijn L, Husebye ES, Karavitaki N, Prete A, Vaidya A, Yedinak C, Dekkers OM (2024) European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab 109:1657\u20131683. https:\/\/doi.org\/10.1210\/clinem\/dgae250","journal-title":"J Clin Endocrinol Metab"},{"key":"13711_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2012.5","volume":"1","author":"VH Morgenroth","year":"2012","unstructured":"Morgenroth VH, Hache LP, Clemens PR (2012) Insights into bone health in Duchenne muscular dystrophy. BoneKEy Rep 1:9. https:\/\/doi.org\/10.1038\/bonekey.2012.5","journal-title":"BoneKEy Rep"},{"key":"13711_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","volume":"16","author":"S Kourakis","year":"2021","unstructured":"Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, Rybalka E (2021) Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better? Orphanet J Rare Dis 16:117. https:\/\/doi.org\/10.1186\/s13023-021-01758-9","journal-title":"Orphanet J Rare Dis"},{"key":"13711_CR11","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1093\/rheumatology\/keaf129","volume":"64","author":"A Crastin","year":"2025","unstructured":"Crastin A, Shanker A, Sagmeister MS, Taylor A, Lavery GG, Raza K, Hardy RS (2025) Vamorolone: a novel metabolism resistant steroid that suppresses joint destruction in chronic polyarthritis with reduced systemic side effects. Rheumatol (Oxford) 64:4371\u20134381. https:\/\/doi.org\/10.1093\/rheumatology\/keaf129","journal-title":"Rheumatol (Oxford)"},{"key":"13711_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","volume":"134","author":"EP Hoffman","year":"2018","unstructured":"Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM (2018) Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134:43\u201352. https:\/\/doi.org\/10.1016\/j.steroids.2018.02.010","journal-title":"Steroids"},{"key":"13711_CR13","doi-asserted-by":"publisher","first-page":"24285","DOI":"10.1073\/pnas.2006890117","volume":"117","author":"X Liu","year":"2020","unstructured":"Liu X, Wang Y, Gutierrez JS, Damsker JM, Nagaraju K, Hoffman EP, Ortlund EA (2020) Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A 117:24285\u201324293. https:\/\/doi.org\/10.1073\/pnas.2006890117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13711_CR14","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201800186","volume":"2","author":"CR Heier","year":"2019","unstructured":"Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF (2019) Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance 2:e201800186. https:\/\/doi.org\/10.26508\/lsa.201800186","journal-title":"Life Sci Alliance"},{"key":"13711_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2025.109689","volume":"223","author":"A de Vera","year":"2025","unstructured":"de Vera A, Clemens PR, Dang UJ, Dutreix C, Gresko E, Guglieri M, Hagerty L, Hasham S, Damsker J, Hathout Y, Linden A, Berglund A, Tobin R, Wahbi K, Hoffman EP (2025) Mineralocorticoid receptor antagonism of vamorolone: evidence from LIONHEART and VISION-DMD clinical trials. Steroids 223:109689. https:\/\/doi.org\/10.1016\/j.steroids.2025.109689","journal-title":"Steroids"},{"key":"13711_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ (2024) Vamorolone: first approval. Drugs 84:111\u2013117. https:\/\/doi.org\/10.1007\/s40265-023-01986-2","journal-title":"Drugs"},{"key":"13711_CR17","unstructured":"(2025) AGAMREE\u00ae Canadian Product Monograph. Retrieved from https:\/\/pdf.hres.ca\/dpd_pm\/00081910.PDF, Accessed on 30th October 2025"},{"key":"13711_CR18","unstructured":"European Medicines Agency (2025) Summary of product characteristics AGAMREE 40 mg\/ml oral suspension. Retrieved from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/agamree-epar-product-information_en.pdf, Accessed on 20th August 2025"},{"key":"13711_CR19","unstructured":"US Food and Drug Administration (2024) US prescribing information AGAMREE 40 mg\/mL oral suspension. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215239s001lbl.pdf, Accessed on 20th August 2025"},{"key":"13711_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","volume":"136","author":"LS Conklin","year":"2018","unstructured":"Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR (2018) Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res 136:140\u2013150. https:\/\/doi.org\/10.1016\/j.phrs.2018.09.007","journal-title":"Pharmacol Res"},{"key":"13711_CR21","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","volume":"93","author":"EP Hoffman","year":"2019","unstructured":"Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Siener C, Jaros M, Shale P, McCall JM, Nagaraju K, van den Anker J, Conklin LS, Cnaan A, Gordish-Dressman H, Damsker JM, Clemens PR, Cooperative International Neuromuscular Research G (2019) Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology 93:e1312\u2013e1323. https:\/\/doi.org\/10.1212\/WNL.0000000000008168","journal-title":"Neurology"},{"key":"13711_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003222","volume":"17","author":"EC Smith","year":"2020","unstructured":"Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, Hagerty L, Dang UJ, Damsker JM, Schwartz BD, Mengle-Gaw LJ, McDonald CM, Cinrg VBP, Investigators D (2020) Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med 17:e1003222. https:\/\/doi.org\/10.1371\/journal.pmed.1003222","journal-title":"PLoS Med"},{"key":"13711_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44178","volume":"5","author":"JK Mah","year":"2022","unstructured":"Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ, NorthStar UKN, Investigators CD (2022) Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open 5:e2144178. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44178","journal-title":"JAMA Netw Open"},{"key":"13711_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, Mah JK, Deconinck N, Goemans N, Haberlova J, Straub V, Mengle-Gaw LJ, Schwartz BD, Harper AD, Shieh PB, De Waele L, Castro D, Yang ML, Ryan MM, McDonald CM, Tulinius M, Webster R, McMillan HJ, Kuntz NL, Rao VK, Baranello G, Spinty S, Childs AM, Sbrocchi AM, Selby KA, Monduy M, Nevo Y, Vilchez-Padilla JJ, Nascimento-Osorio A, Niks EH, de Groot IJM, Katsalouli M, James MK, van den Anker J, Damsker JM, Ahmet A, Ward LM, Jaros M, Shale P, Dang UJ, Hoffman EP (2022) Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol 79:1005\u20131014","journal-title":"JAMA Neurol"},{"key":"13711_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/clinem\/dgae521","volume":"110","author":"A Ahmet","year":"2025","unstructured":"Ahmet A, Tobin R, Dang UJ, Rooman R, Guglieri M, Clemens PR, Hoffman EP, Ward LM (2025) Adrenal suppression from vamorolone and prednisone in Duchenne muscular dystrophy: results from the phase 2b clinical trial. J Clin Endocrinol Metab 110:334\u2013344. https:\/\/doi.org\/10.1210\/clinem\/dgae521","journal-title":"J Clin Endocrinol Metab"},{"key":"13711_CR26","unstructured":"OPTIMIZE DMD Adrenal Insufficiency Working Group (2025) Vamorolone (AGAMREE\u00ae) Information Sheet for Families. Retrieved from https:\/\/optimizedmd.org\/for-patients-and-families\/, Accessed on 21st July 2025"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13711-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:09:45Z","timestamp":1774516185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13711-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["13711"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13711-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hanns Lochm\u00fcller\/HL: Consultancy and financial support for research projects and clinical trials: Amplo Biotechnology, AMO Pharma, Argenx, Biogen, Desitin, Fulcrum Therapeutics, Harmony Biosciences, KYE Pharmaceuticals, Milo Biotechnology, Novartis, Pfizer, PTC Therapeutics, Hoffman-La Roche, Sanofi-Genzyme, Santhera Pharmaceuticals, Sarepta, Satellos, Spark Therapeutics, Ultragenyx. Hernan Gonorazky\/HG: clinical trial investigator: Pfizer, Santhera Pharmaceuticals; advisor: Kye Pharma, Novartis, Roche, Solid Biosciences; grants: Muscular Dystrophy Canada. Elisa Nigro\/EN: no disclosures. Jean K. Mah\/JKM: clinical trial investigator: Biogen, Italfarmaco SpA, NS Pharma, Pfizer, PTC Therapeutics, ReveraGen Biopharma, Roche, Santhera Pharmaceuticals, Sarepta Therapeutics. Alberto Alem\u00e1n\/AA: clinical trial investigator: ReveraGen BioPharma, Santhera Pharmaceuticals, Pfizer. Amanda Yaworski\/AY: consultant: Novartis, Biogen, Roche. Maryam Oskoui\/MO: clinical trial investigator: Novartis Pharmaceuticals, Roche Genentech, Santhera Pharmaceuticals. Anne Marie Sbrocchi\/AMS: clinical trial investigator: Ultragenyx, Santhera Pharmaceuticals; consultant: Catalyst, Kyowa Kirin. Kathryn Selby\/KS: clinical trial investigator: Santhera Pharmaceuticals. Ana de Vera\/AdV, Ekaterina Gresko\/EG, Aki Linden\/AL, Catherine Dutreix\/CD: employees of Santhera Pharmaceuticals. Laura McAdam\/LM: Clinical trial investigator: Italfarmaco SpA, Santhera, Anavex Life sciences; consulting: Acadia Pharmaceuticals, Kye therapeutics. Eric P. Hoffman\/EPH: stock ownership: ReveraGen BioPharma, AGADA BioSciences; employee: ReveraGen, AGADA BioSciences; clinical trial investigator: Santhera Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The clinical study protocol and all amendments, informed consent form (ICF), and any other appropriate documents were approved by the Institutional Review Board (IRB)\/Independent Ethics Committee (IEC) prior to the start of the study at each of the five recruitment sites (Alberta Children\u2019s Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada; Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; The University of British Columbia, Children's and Women's Health Centre, Vancouver, British Columbia, Canada).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The parent\/legal guardian for each participant provided written consent using the ICF before any study procedures began. Written or verbal assent was also obtained from each participant as required per local regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"177"}}